PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Nephritis

Drugs in development · updated 30 October 2026

Nephritis: drugs in development

As of 30 October 2026 there are 9 active clinical trials (recruiting or ongoing, phases I–III) on 7 drugs for nephritis. 5 are experimental, that is not yet approved in the United States.

9Active trials
5Experimental drugs
4Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
BHV-1400III2NCT07642050
JADE101III2NCT07902817
IanalumabVAY736III1NCT05126277
ZigakibartBION-1301III1NCT06858319
PS-002I–II1NCT07182227

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
RituximabRuxience, RituxanIII1NCT05696613
AtaciceptTrutakna®II1NCT06983028

Sorted by most advanced phase and number of active trials.

All 7 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009393 “Nephritis”.

ItalianoFrançaisDeutsch